{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:26:05Z","timestamp":1787311565489,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Capacity Enhancement Project","award":["JSPH-MB-2022-18"],"award-info":[{"award-number":["JSPH-MB-2022-18"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61973335"],"award-info":[{"award-number":["61973335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Disitamab vedotin (RC48-ADC), an antibody-drug conjugate (ADC), combines specific antibody disitamab with cytotoxicity monomethyl auristatin E to effectively target the human epidermal growth factor receptor 2 (HER2) protein on tumor cells for precise elimination. Recent studies have demonstrated that RC48-ADC offers therapeutic benefits for patients with HER2-positive and HER2-low-expression breast cancer (BC). However, a thorough exploration of its efficacy and safety in real-world settings for patients with metastatic breast cancer (mBC) is currently lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multicenter, real-world study included patients with mBC who received RC48-ADC from September 2021 to March 2024. These patients include HER2-positive BC and HER2-low-expression BC. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), restricted mean survival time, objective response rate (ORR), and disease control rate (DCR). Factors affecting efficacy and the occurrence of treatment-related adverse events (TRAE) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included a cohort of 89 patients with mBC, with 48 of those being identified as HER2-positive. As of March 2024, 22 deaths were recorded, with an immature median OS. Total PFS varied from 1.0 to 31.2 months, with a median of 5.5 months (95% CI, 4.368-6.632). HER2-positive patients exhibited prolonged PFS compared with HER2-low-expression patients (6.6 months vs 4.1 months, P\u2005=\u2005.023). The overall ORR stood at 25.8% (95% CI, 0.178-0.358), with higher rates observed in HER2-positive patients compared with HER2-low-expression patients (31.3% vs 19.5%). Similarly, the overall DCR was 78.7% (95% CI, 0.691-0.859), with HER2-positive patients demonstrating superior DCR compared with HER2-low-expression patients (83.3% vs 73.2%). Notably, HER2 expression emerged as the primary determinant of RC48-ADC efficacy. The most prevalent TRAE among all patients included leukopenia (21.3%) and alopecia (20.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RC48-ADC showcases promising efficacy and manageable safety in patients with both HER2-positive and HER2-low-expression mBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae304","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T15:16:46Z","timestamp":1729437406000},"source":"Crossref","is-referenced-by-count":9,"title":["Real-world application of disitamab vedotin (RC48-ADC) in patients with\u00a0breast cancer with different HER2 expression levels: efficacy and safety analysis"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9353-5542","authenticated-orcid":false,"given":"Ke","family":"Wang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University Department of Oncology, , Nanjing 210009 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2138-0572","authenticated-orcid":false,"given":"Ting","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University Department of Chemotherapy, , Nanjing 210009 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University Department of Oncology, , Nanjing 210009 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2060-5969","authenticated-orcid":false,"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University Department of Chemotherapy, , Nanjing 210009 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-0046","authenticated-orcid":false,"given":"Xiaoxiang","family":"Guan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University Department of Oncology, , Nanjing 210009 ,","place":["People\u2019s Republic of China"]},{"name":"Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University , Nanjing 210029 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2867-562X","authenticated-orcid":false,"given":"Chengjun","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University Department of Oncology, , Nanjing 210009 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"2025082905265426400_CIT0001","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025082905265426400_CIT0002","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025082905265426400_CIT0003","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"2025082905265426400_CIT0004","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"2025082905265426400_CIT0005","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"2025082905265426400_CIT0006","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/s1470-2045(21)00288-6","article-title":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG).\u00a0Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025082905265426400_CIT0007","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025082905265426400_CIT0008","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2025082905265426400_CIT0009","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025082905265426400_CIT0010","doi-asserted-by":"publisher","first-page":"104189","DOI":"10.1016\/j.critrevonc.2023.104189","article-title":"The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: a systematic review","volume":"192","author":"Filis","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025082905265426400_CIT0011","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","article-title":"Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry","volume":"46","author":"Hong","year":"2023","journal-title":"Arch Pharm Res"},{"key":"2025082905265426400_CIT0012","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025082905265426400_CIT0013","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody-drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2025082905265426400_CIT0014","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"2025082905265426400_CIT0015","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025082905265426400_CIT0016","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S1470-2045(18)30918-5","article-title":"T-DM1 for residual, invasive, HER2-positive breast cancer","volume":"20","author":"Burki","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025082905265426400_CIT0017","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"key":"2025082905265426400_CIT0018","doi-asserted-by":"publisher","first-page":"113371","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 low protein expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025082905265426400_CIT0019","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11864-019-0633-6","article-title":"Antibody-drug conjugates in breast cancer: a comprehensive review","volume":"20","author":"Pond\u00e9","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"2025082905265426400_CIT0020","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"2025082905265426400_CIT0021","doi-asserted-by":"publisher","first-page":"103883","DOI":"10.1016\/j.critrevonc.2022.103883","article-title":"HER2-low breast cancer: novel detections and treatment advances","volume":"181","author":"Wu","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025082905265426400_CIT0022","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082905265426400_CIT0023","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"key":"2025082905265426400_CIT0024","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"2025082905265426400_CIT0025","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025082905265426400_CIT0026","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II Study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025082905265426400_CIT0027","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"2025082905265426400_CIT0028","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ijms20051115","article-title":"HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025082905265426400_CIT0029","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025082905265426400_CIT0030","volume-title":"National Cancer Institute Common Terminology Criteria for Adverse Events, NCI-CTCAE 5.0 [Z]","year":"2017"},{"key":"2025082905265426400_CIT0031","doi-asserted-by":"publisher","first-page":"PD4","DOI":"10.1158\/1538-7445.sabcs19-pd4-06","article-title":"Abstract PD4-06: early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res"},{"key":"2025082905265426400_CIT0032","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1200\/jco.2021.39.15_suppl.1022","article-title":"RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies","volume":"39","author":"Wang","year":"2021","journal-title":"JCO"},{"key":"2025082905265426400_CIT0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"1","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"2025082905265426400_CIT0034","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.2018.36.15_suppl.1014","article-title":"A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer","volume":"36","author":"Saura","year":"2018","journal-title":"JCO"},{"key":"2025082905265426400_CIT0035","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025082905265426400_CIT0036","doi-asserted-by":"publisher","first-page":"1183514","DOI":"10.3389\/fphar.2023.1183514","article-title":"Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low\/positive advanced breast cancer: a single-arm meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025082905265426400_CIT0037","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2025082905265426400_CIT0038","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025082905265426400_CIT0039","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"2025082905265426400_CIT0040","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"key":"2025082905265426400_CIT0041","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10585-016-9784-z","article-title":"Characterization of passive permeability at the blood\u2013tumor barrier in five preclinical models of brain metastases of breast cancer","volume":"33","author":"Adkins","year":"2016","journal-title":"Clin Exp Metastasis"},{"key":"2025082905265426400_CIT0042","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10585-015-9740-3","article-title":"Activity of T-DM1 in Her2-positive breast cancer brain metastases","volume":"32","author":"Bartsch","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"2025082905265426400_CIT0043","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1200\/jco.2022.40.17_suppl.lba3","article-title":"Trastuzumab deruxtecan (T-DXd) versus treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): updated survival results of the randomized, phase III DESTINY-Breast04 study","volume":"34","author":"Modi","year":"2023","journal-title":"Ann Oncol"},{"key":"2025082905265426400_CIT0044","doi-asserted-by":"publisher","first-page":"PD3","DOI":"10.1158\/1538-7445.sabcs20-pd3-06","article-title":"Abstract PD3-06: updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer","volume":"81","author":"Modi","year":"2021","journal-title":"Cancer Res"},{"key":"2025082905265426400_CIT0045","doi-asserted-by":"publisher","first-page":"CT167","DOI":"10.1158\/1538-7445.am2021-ct167","article-title":"Abstract CT167: pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies","volume":"81","author":"Powell","year":"2021","journal-title":"Cancer Res"},{"key":"2025082905265426400_CIT0046","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab\u2013drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae304\/60702586\/oyae304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae304\/60702586\/oyae304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:00Z","timestamp":1756459620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae304\/7902202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae304","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,11,16]]},"article-number":"oyae304"}}